Introduction: Preeclampsia and eclampsia are life-threatening emergencies and require immediate management to decrease maternal morbidity and mortality. Magnesium sulfate (MgSO₄) is primarily used in the treatment. To overcome the problem of toxicity, studies have been conducted to determine the lowest effective and safe dose of MgSO₄. Methodology: The study was a randomized controlled study, conducted on pregnant women diagnosed with severe preeclampsia and eclampsia in Jawaharlal Nehru Medical College Hospital, Aligarh Muslim University, Aligarh, Uttar Pradesh, India from September 2015 to November 2017. A total of 260 cases were randomly allocated into very-low-dose (0.5 gm/hour), low-dose (0.75 gm/hour), and standard-dose groups (1 gm/hour). Maternal and perinatal outcomes were noted, and statistical analysis was done. Results: Maternal and perinatal outcomes were comparable in all three groups. Recurrent convulsion rates in very-low-dose, low-dose, and standard-dose groups were 13.7, 5.4, and 14.2%, respectively. The amount of drug used in the very low-dose (0.5 gm/hour) was 42.6% less than the standard dose (1.0 gm/hour) and 25% less than the low-dose group (0.75 gm/hour). The results were highly significant (p ≤ 0.001) in both cases on statistical analysis. Conclusion: Low-dose of MgSO₄ was found to be effective in controlling convulsions with less toxicity and complication rate.